2 active not recruiting. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 2 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow CNV: new trials by email Literature Review of CNV trials Research Report on CNV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®) - AMD, nAMD | Phase 3 | Active not recruiting | AbbVie | 735 | 2022-01-13 | 2026-08-03 |
| Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD ABBV-RGX-314, Ranibizumab (LUCENTIS®) - AMD, nAMD | Phase 2 / Phase 3 | Active not recruiting | AbbVie | 671 | 2020-12-29 | 2026-04-28 |
Choroidal Neovascularization (2) · Eye Diseases (2) · Macular Degeneration (2) · Retinal Degeneration (2) · Retinal Diseases (2) · Wet Macular Degeneration (2)
Choroid Diseases (2) · Eye Diseases, Hereditary (2) · Metaplasia (2) · Neovascularization, Pathologic (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Uveal Diseases (2)
Ranibizumab (1) · aflibercept (1)
AbbVie (2)
United States (2) · Canada (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Japan (1) · Puerto Rico (1) · Spain (1) · United Kingdom (1)